Business Description
Genfit SA
ISIN : FR0004163111
Share Class Description:
XPAR:GNFT: Ordinary SharesCompare
Compare
Traded in other countries / regions
GNFT.FranceGNFT.USA0QT6.UKXUP.Germany IPO Date
2006-12-19Description
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.11 | |||||
| Equity-to-Asset | 0.39 | |||||
| Debt-to-Equity | 1.03 | |||||
| Debt-to-EBITDA | N/A |
N/A
|
N/A
| |||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -1.45 | |||||
| Beneish M-Score | -0.84 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 206.3 | |||||
| 3-Year EBITDA Growth Rate | 41.4 | |||||
| 3-Year EPS without NRI Growth Rate | 36.3 | |||||
| 3-Year FCF Growth Rate | 22.5 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 47.27 | |||||
| 9-Day RSI | 41.03 | |||||
| 14-Day RSI | 42.88 | |||||
| 6-1 Month Momentum % | 33.33 | |||||
| 12-1 Month Momentum % | 34.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.94 | |||||
| Quick Ratio | 2.94 | |||||
| Cash Ratio | 2.02 | |||||
| Days Sales Outstanding | 174.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.7 | |||||
| Shareholder Yield % | 1.19 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -339.03 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 6.43 | |||||
| PS Ratio | 10.86 | |||||
| PB Ratio | 2.73 | |||||
| Price-to-Tangible-Book | 9.55 | |||||
| EV-to-Revenue | 10.43 | |||||
| EV-to-Forward-Revenue | 1.95 | |||||
| EV-to-FCF | -3.08 | |||||
| Price-to-Net-Current-Asset-Value | 26.61 | |||||
| FCF Yield % | -31.18 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers